The National Acoustic Laboratories' (NAL) new procedure for selecting the gain and frequency response of a hearing aid

A new procedure is presented for selecting the gain and frequency response of a hearing aid from pure-tone thresholds. This was developed from research which showed that a previous procedure did not meet its aim of amplifying all frequency bands of speech to equal loudness but that frequency responses which did so were considerably more effective. Measurements of 30 sensorineurally hearing-impaired ears (27 subjects), together with data from other studies, were analyzed to determine the best formula for predicting the optimal frequency response, for each individual, from the audiogram. The analysis indicated that a flat audiogram would require a rising frequency response characteristic of about 8 dB/octave up to 1.25 kHz and thereafter a falling characteristic of about 2 dB/octave. Variations in audiogram slope required about one-third as much variation in response slope. Three frequency average (3FA) gain was calculated to equal the 3FA gain of the previous procedure. Forty-four subjects (67 aided ears) fitted by the new procedure were evaluated by paired comparison judgments of the intelligibility and pleasantness of speech. The prescribed frequency response was seldom inferior to, and usually better than, any of several variations having more, or less, low and/or high-frequency amplification. On the average, used gain was approximately equal to prescribed gain. It is concluded that the new formula should prescribe a near optimal frequency response with few exceptions.

Speech recognition of hearing-impaired listeners: predictions from audibility and the limited role of high-frequency amplification

Two experiments were conducted to examine the relationship between audibility and speech recognition for individuals with sensorineural hearing losses ranging from mild to profound degrees. Speech scores measured using filtered sentences were compared to predictions based on the Speech Intelligibility Index (SII). The SII greatly overpredicted performance at high sensation levels, and for many listeners, it underpredicted performance at low sensation levels. To improve predictive accuracy, the SII needed to be modified. Scaling the index by a multiplicative proficiency factor was found to be inappropriate, and alternative modifications were explored. The data were best fitted using a method that combined the standard level distortion factor (which accounted for decrease in speech intelligibility at high presentation levels based on measurements of normal-hearing people) with individual frequency-dependent proficiency. This method was evaluated using broadband sentences and nonsense syllables tests. Results indicate that audibility cannot adequately explain speech recognition of many hearing-impaired listeners. Considerable variations from audibility-based predictions remained, especially for people with severe losses listening at high sensation levels. The data suggest that, contrary to the basis of the SII, information contained in each frequency band is not strictly additive. The data also suggest that for people with severe or profound losses at the high frequencies, amplification should only achieve a low or zero sensation level at this region, contrary to the implications of the unmodified SII.

Follicular lymphoma in the United States: first report of the national LymphoCare study

PURPOSE

Optimal therapy of follicular lymphoma (FL) is not defined. We analyzed a large prospective cohort study to identify current demographics and patterns of care of FL in the United States.

PATIENTS AND METHODS

The National LymphoCare Study is a multicenter, longitudinal, observational study designed to collect information on treatment regimens and outcomes for patients with newly diagnosed FL in the United States. Patients were enrolled between 2004 and 2007. There is no study-specific prescribed treatment regimen or intervention.

RESULTS

Two thousand seven hundred twenty-eight subjects were enrolled at 265 sites, including the 80% of patients enrolled from nonacademic sites. Using the Follicular Lymphoma International Prognostic Index (FLIPI), three distinct groups independent of histologic grade could be defined. Initial therapeutic strategy was: observation, 17.7%; rituximab monotherapy, 13.9%; clinical trial 6.1%; radiation therapy, 5.6%; chemotherapy only, 3.2%; chemotherapy plus rituximab, 51.9%. Chemotherapy plus rituximab regimens were: rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone, 55.0%; rituximab plus cyclophosphamide, vincristine, and prednisone, 23.1%; rituximab plus fludarabine based, 15.5%; other, 6.4%. The choice to initiate therapy rather than observe was associated with age, FLIPI, stage, and grade (P < .01). Significant differences in treatment (P < .01) across regions of the United States were noted. Contrary to practice guidelines, treatment of stage I FL frequently omits radiation therapy.

CONCLUSION

Widely disparate therapeutic approaches are utilized for FL. Initial therapy is deferred in a small subset of patients. There is no single standard of care for the treatment of de novo FL, although antibody use is ubiquitous when therapy is initiated. These disparate approaches to the initial care of patients with FL render a heterogeneous group of patients at relapse.

Binaural-bimodal fitting or bilateral implantation for managing severe to profound deafness: a review

There are now many recipients of unilateral cochlear implants who have usable residual hearing in the non-implanted ear. To avoid auditory deprivation and to provide binaural hearing, a hearing aid or a second cochlear implant can be fitted to that ear. This article addresses the question of whether better binaural hearing can be achieved with binaural/bimodal fitting (combining a cochlear implant and a hearing aid in opposite ears) or bilateral implantation. In the first part of this article, the rationale for providing binaural hearing is examined. In the second part, the literature on the relative efficacy of binaural/bimodal fitting and bilateral implantation is reviewed. Most studies on comparing either mode of bilateral stimulation with unilateral implantation reported some binaural benefits in some test conditions on average but revealed that some individuals benefited, whereas others did not. There were no controlled comparisons between binaural/bimodal fitting and bilateral implantation and no evidence to support the efficacy of one mode over the other. In the third part of the article, a crossover trial of two adults who had binaural/bimodal fitting and who subsequently received a second implant is reported. The findings at 6 and 12 months after they received their second implant indicated that binaural function developed over time, and the extent of benefit depended on which abilities were assessed for the individual. In the fourth and final parts of the article, clinical issues relating to candidacy for binaural/ bimodal fitting and strategies for bimodal fitting are discussed with implications for future research.

Optimal outcome measures, research priorities, and international cooperation

The participants in the Eriksholm Workshop on "Measuring Outcomes in Audiological Rehabilitation Using Hearing Aids" debated three issues that are reported in this article. First, it was agreed that the characteristics of an optimal outcome measure vary as a function of the purpose of the measurement. Potential characteristics of outcome self-report tools for four common goals of outcome measurement are briefly presented to illustrate this point. Second, 10 important research priorities in outcome measurement were identified and ranked. They are presented with brief discussion of the top five. Third, the concept of generating a brief universally applicable outcome measure was endorsed. This brief data set is intended to supplement existing outcome measures and to promote data combination and comparison across different social, cultural, and health-care delivery systems. A set of seven core items is proposed for further study.

Should children who use cochlear implants wear hearing aids in the opposite ear?

OBJECTIVE

The aim of this study was to investigate 1) whether a hearing aid needs to be adjusted differently depending on whether a child wears a cochlear implant or another hearing aid in the contralateral ear; 2) whether the use of a hearing aid and a cochlear implant in opposite ears leads to binaural interference; and 3) whether the use of a hearing aid and a cochlear implant in opposite ears leads to binaural benefits in speech perception, localization, and communicative functioning in real life.

DESIGN

Sixteen children participated in this study. All children used a Nucleus 22 or Nucleus 24 cochlear implant system programmed with the SPEAK strategy in one ear. The hearing aid amplification requirements in the nonimplanted ear of these children were determined using two procedures. A paired comparison technique was used to identify the frequency response that was best for speech intelligibility in quiet, and a loudness balancing technique was used to match the loudness of speech in the ear with a hearing aid to that with a cochlear implant. Eleven of the 16 children participated in the investigation of binaural effects. Performance in speech perception, localization, and communicative functioning was assessed under four aided conditions: cochlear implant with hearing aid as worn, cochlear implant alone, hearing aid alone, and cochlear implant with hearing aid adjusted according to individual requirements.

RESULTS

Fifteen of the 16 children whose amplification requirements were determined preferred a hearing aid frequency response that was within +/-6 dB/octave of the NAL-RP prescription. On average, the children required 6 dB more gain than prescribed to balance the loudness of the implanted ear for a speech signal presented at 65 dB SPL. For all 11 children whose performance was evaluated for investigating binaural effects, there was no indication of significantly poorer performance under bilaterally aided conditions compared with unilaterally aided conditions. On average, there were significant benefits in speech perception, localization, and aural/oral function when the children used cochlear implants with adjusted hearing aids than when they used cochlear implants alone. All individuals showed benefits in at least one of the measures.

CONCLUSIONS

Hearing aids for children who also use cochlear implants can be selected using the NAL-RP prescription. Adjustment of hearing aid gain to match loudness in the implanted ear can facilitate integration of signals from both ears, leading to better speech perception. Given that there are binaural advantages from using cochlear implants with hearing aids in opposite ears, clinicians should advise parents and other professionals about these potential advantages, and facilitate bilateral amplification by adjusting hearing aids after stable cochlear implant MAPs are established.

Compression? Yes, but for low or high frequencies, for low or high intensities, and with what response times?

Several rationales for using compression in hearing aids are outlined. These rationales comprise discomfort avoidance, loudness normalization, noise reduction, short term signal dynamic range reduction, empirically determined compression, and long-term signal dynamic range reduction. The compression systems needed to implement each of these differ greatly, and these differences can be viewed as differences in the frequency range undergoing most compression, the intensity range undergoing most compression, and the speed at which the compressor(s) operate. A classification system along these lines is introduced and examples of currently available hearing aids falling into each category are given. The effects of each type of compression on speech intelligibility is investigated via a review of published research. The results of this indicate that, for speech in quiet at a comfortable level, no compression scheme yet tested offers better intelligibility than individually selected linear amplification. If input level is then decreased and the aid wearer is prevented from adjusting the volume control, many types of compression provide intelligibility superior to that available from linear amplification. In broadband noise, only one system, containing wideband compression followed by fast acting high-frequency compression, has so far been shown to provide significant intelligibility advantages.

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Lymphoblastic Leukemia in Adults: An Evidence-based Review

Evidence supporting the role of hematopoietic stem cell transplantation (SCT) in the therapy of acute lymphoblastic leukemia in adults (> or =15 years) is presented and critically evaluated in this systematic evidence-based review. Specific criteria were used for searching the published medical literature and for grading the quality and strength of the evidence, and the strength of the treatment recommendations. Treatment recommendations based on the evidence are presented and were reached unanimously by a panel of acute lymphoblastic leukemia experts. The priority areas of needed future research for adult acute lymphoblastic leukemia are: definition of patients at high risk in first complete remission, beyond Philadelphia chromosome positive; outcomes of SCT in older (>50 years) adults; determination if reduced intensity versus myeloablative conditioning regimens yield an equivalent graft-versus-leukemia effect with reduced toxicity; monitoring of minimal residual disease to achieve disease control before SCT; and the use of cord blood and other alternative sources of stem cells for use in adult SCT recipients.

Electrophysiological and behavioral evidence of auditory processing deficits in children with reading disorder☆

OBJECTIVE

The aim of the research was to investigate auditory processing abilities in children with reading disorders using electrophysiological and behavioral tasks.

METHODS

Differences in auditory processing between control, compensated (age appropriate reading skills with a history of reading disorder), and reading disordered groups were systematically investigated.

RESULTS

The reading disorder group had significantly lower results than control and compensated reader groups for most tests in the reading and auditory processing test battery. All children with a reading disorder did not pass at least one behavioral test of auditory processing, and hence would be diagnosed clinically as having an auditory processing disorder (APD). The reading disorder group also had significantly smaller /ga/-evoked mismatch negativity (MMN) area than the control group. Compensated and control groups had similar results for the electrophysiological and behavioral auditory processing tests. Correlation analyses showed that reading fluency and accuracy and nonword scores (measured using Castle and Coltheart's word/nonword test) correlated significantly with most APD measures.

CONCLUSIONS

The general profile of auditory processing deficits in children with reading disorder was a combination of deficits on frequency patterns (i.e. frequency pattern test) and absent or small /ga/-evoked MMN. Significant results from the correlation analyses support the co-morbidity of reading and auditory processing disorders.

SIGNIFICANCE

Children with reading disorders are likely to have auditory processing disorders.

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006 evidence-based review

Clinical research published since the first evidence-based review on the role of hematopoietic stem cell transplantation (SCT) in the treatment of acute lymphoblastic leukemia (ALL) in adults is presented and critically evaluated in this update. Treatment recommendations changed or modified based on new evidence include: (1) myeloablative allogeneic SCT is an appropriate treatment for adult (<35 years) ALL in first complete remission for all disease risk groups; and (2) reduced-intensity conditioning may produce similar outcomes to myeloablative regimens. Treatment recommendations unchanged or strengthened by new evidence include: (1) allogeneic SCT is recommended over chemotherapy for ALL in second complete remission or greater; (2) allogeneic is superior to autologous SCT; and (3) there are similar survival outcomes after related and unrelated allogeneic SCT. New treatment recommendations based on new evidence include: (1) in the absence of a suitable allogeneic donor, autologous SCT may be an appropriate therapy, but results in a high relapse rate; (2) it is appropriate to consider cord blood transplantation for patients with no HLA well-matched donor; and (3) imatinib therapy before and/or after SCT (for Ph+ ALL) yields significantly superior survival outcomes. Areas of needed research in the treatment of adult ALL with SCT were identified and presented in the review.

Maximizing effective audibility in hearing aid fitting

OBJECTIVE

This paper examines why more audibility is not always better than less audibility if hearing-impaired people are to best understand speech.

DESIGN

We used speech perception data from 14 normally hearing and 40 hearing-impaired people to quantify the contribution of audibility to speech intelligibility. The quantification revealed that the effectiveness of audibility decreased with hearing loss, and the decrement was greater at high frequencies than at lower frequencies. To apply the Speech Intelligibility Index (SII) model to predict speech intelligibility for hearing-impaired people, we modified the model to take account of effective audibility rather than physical audibility.

RESULTS

The modified SII model provided an adequate description of speech performance of people with a wide range of hearing threshold levels. We applied the model to the evaluation of two prescriptions for a sloping audiogram at prescribed levels and at equated loudness levels to demonstrate the necessity of considering loudness and effective audibility in prescribing amplification. Effective audibility is defined as audibility corrected for the effects of level distortion and hearing loss desensitization, and this paper proposes a method of estimating effective audibility from hearing threshold level at different frequencies.

CONCLUSIONS

The practical implication of considering effective audibility in prescribing hearing aids is that for a given listening level, less gain is provided at frequencies where the hearing is most impaired to allow more gain at frequencies where audibility is most useful. In developing the NAL-NL1 prescription for nonlinear hearing aids, we adopted the modified SII model together with a loudness model to derive optimal gain-frequency response characteristics that maximize predicted speech intelligibility for people with different degrees of hearing losses.

Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices

BACKGROUND

Because follicular lymphoma (FL) patients have heterogeneous outcomes, the FL international prognostic index (FLIPI) was developed to risk-stratify patients and to predict survival. However, limited data exist regarding the role of FLIPI in the era of routine first-line rituximab (R) and R-chemotherapy regimens and in the setting of community oncology practices.

PATIENTS AND METHODS

We evaluated the outcome data from the National LymphoCare Study (NLCS), a prospective, observational cohort study, which collects data on patients with FL in the United States (US) community practices.

RESULTS

Among 1068 male and 1124 female patients with FLIPI data, most were treated in US community practices (79%); 35% were FLIPI good risk, 30% intermediate risk, and 35% poor risk. FLIPI risk groups were significant predictors of overall survival (OS) and progression-free survival (PFS) for patients who undergo watchful waiting (WW), and those who receive non-R-containing regimens, R-alone, and R-chemotherapy combinations.

CONCLUSIONS

In the setting of contemporary practice with routine R use, stratifying patients into good, intermediate, and poor FLIPI risk groups predicts distinct outcomes in terms of OS and PFS. FLIPI remains an important prognostic index in the R era and should be used in clinical practices to support discussions about prognosis.

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Lymphoblastic Leukemia in Children: An Evidence-Based Review

Evidence supporting the role of hematopoietic stem cell transplantation (SCT) in the therapy of acute lymphoblastic leukemia (ALL) in children is presented and critically evaluated in this systematic evidence-based review. Specific criteria were used for searching the published literature and for grading the quality and strength of the evidence and the strength of the treatment recommendations. Treatment recommendations based on the evidence are presented in a table in this review (Summary of Treatment Recommendations Made by the Expert Panel for Pediatric Acute Lymphoblastic Leukemia) and were reached unanimously by a panel of ALL experts. The priority areas of needed future research in pediatric ALL are unrelated marrow or blood donor versus unrelated cord blood donor allogeneic SCT; alternative, nonfamily allogeneic donor versus autologous SCT; better methods for identifying high-relapse-risk patients; assessments of the effect of current chemotherapy regimens on early relapse; and use of pre-SCT detection of minimal residual disease to predict post-SCT outcomes.

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006 evidence-based review

Clinical research published since the first evidence-based review on the role of hematopoietic stem cell transplantation (SCT) in the treatment of acute lymphoblastic leukemia (ALL) in adults is presented and critically evaluated in this update. Treatment recommendations changed or modified based on new evidence include: (1) myeloablative allogeneic SCT is an appropriate treatment for adult (<35 years) ALL in first complete remission for all disease risk groups; and (2) reduced-intensity conditioning may produce similar outcomes to myeloablative regimens. Treatment recommendations unchanged or strengthened by new evidence include: (1) allogeneic SCT is recommended over chemotherapy for ALL in second complete remission or greater; (2) allogeneic is superior to autologous SCT; and (3) there are similar survival outcomes after related and unrelated allogeneic SCT. New treatment recommendations based on new evidence include: (1) in the absence of a suitable allogeneic donor, autologous SCT may be an appropriate therapy, but results in a high relapse rate; (2) it is appropriate to consider cord blood transplantation for patients with no HLA well-matched donor; and (3) imatinib therapy before and/or after SCT (for Ph+ ALL) yields significantly superior survival outcomes. Areas of needed research in the treatment of adult ALL with SCT were identified and presented in the review.

Motivation for health information seeking and processing about clinical trial enrollment

Low patient accrual in clinical trials poses serious concerns for the advancement of medical science in the United States. Past research has identified health communication as a crucial step in overcoming barriers to enrollment. However, few communication scholars have studied this problem from a sociopsychological perspective to understand what motivates people to look for or pay attention to information about clinical trial enrollment. This study applies the model of Risk Information Seeking and Processing (RISP) to this context of health decision making. By recognizing the uncertainties embedded in clinical trials, we view clinical trial enrollment as a case study of risk. With data from a random-digit-dial telephone survey of 500 adults living in the United States, we used structural equation modeling to test the central part of the RISP model. In particular, we examined the role of optimistic feelings, as a type of positive affect, in motivating information seeking and processing. Our results indicated that rather than exerting an indirect influence on information seeking through motivating a psychological need for more information, optimistic feelings have more direct relationships with information seeking and processing. Similarly, informational subjective norms also exhibit a more direct relationship with information seeking and processing. These results suggest merit in applying the RISP model to study health decision making related to clinical trial enrollment. Our findings also render practical implications on how to improve communication about clinical trial enrollment.

The National Acoustic Laboratories' procedure for selecting the saturation sound pressure level of hearing aids: theoretical derivation

This paper presents the derivation of a procedure for prescribing the saturation sound pressure level (SSPL) of hearing aids. The procedure is designed to be used with either measured values of loudness discomfort level (LDL) or with hearing threshold values alone. SSPL needs to be low enough to prevent the hearing aid from causing loudness discomfort to the aid wearer but high enough to prevent the hearing aid from being excessively saturated by speech. The maximum SSPL likely to be acceptable can be predicted by measuring LDL or by estimating LDL from hearing thresholds. The minimum SSPL likely to be acceptable can be predicted by calculating, for any particular hearing loss, the amount of gain likely to be needed and hence the SSPL needed if the speech input signal is continuous discourse at an overall level of 75 dB SPL. The midpoint between the minimum and maximum acceptable SSPL values is defined as the optimal or prescribed SSPL, and the three frequency average (3FA; 500, 1000, and 2000 Hz) value of this can be predicted from the 3FA hearing thresholds. Alternatively, the SSPL prescription at each frequency can be prescribed on the basis of the hearing aid gain at each frequency. For either method, the SSPL prescription needs to be increased for people with a conductive component to their hearing losses. The SSPL prescription, when referred to a 2-cc coupler, needs to be decreased for infants, for deeply inserted hearing aids, for multichannel hearing aids that limit SSPL separately in each band, and possibly for nonlinear hearing aids. The 3FA SSPL prescribed for persons with a sensorineural hearing loss increases linearly from 89 dB SPL for normal hearing to 107 dB SPL for a person with a 60 dB HL 3FA loss, and then linearly again to 139 dB SPL for a person with a 120 dB HL 3FA loss. The procedure predicts that the acceptable range of SSPLs is very wide for people with mild losses but is vanishingly small for people with profound losses.

Challenges with Novel Clinical Trial Designs: Master Protocols

The 2018 Accelerating Anticancer Agent Development (AAADV) Workshop assembled a panel of experts for an in-depth discussion session to present "Challenges with Novel Clinical Trial Designs." This panel offered assessments of the challenges faced by industry, the FDA, investigators, institutional review boards, and patients. The panel focused on master protocols, which include umbrella trials, platform trials, and basket trials. Umbrella trials and platform trials share many commonalities, whereas basket trials are more distinct. Umbrella and platform trials are generally designed with multiple arms where patients of the same histology or other unifying characteristics are enrolled into different arms and multiple investigational agents are evaluated in a single protocol. In contrast, basket studies generally enroll patients with different tumor types based on the presence of a specific mutation or biomarker regardless of histology; these trials may include expansion cohorts. These novel designs offer the promise of expedited drug assessment and approval, but they also place new challenges on all the stakeholders involved in the drug development process. Only by identifying the challenges of these complex, innovative clinical trial designs and highlighting challenges from each perspective can we begin to address these challenges. The 2018 AAADV Workshop convened a panel of experts from relevant disciplines to highlight the challenges that are created by master protocols, and, where appropriate, offer strategies to address these challenges.

Sound field audiometry: recommended stimuli and procedures

Comprehensive recommendations are presented for conducting sound field audiometry with frequency specific stimuli. These recommendations are primarily based on a series of investigations by the authors. The rationale for each recommendation is presented, together with a brief overview of the supporting research. The preferred stimuli are frequency modulation tones, triangularly or sinusoidally modulated at a rate of about 20 Hz, or suitably generated narrow bands of noise. The optimal bandwidths of the stimuli, expressed in percentages of the center frequency, vary with frequency. Stimuli suitable for most purposes have bandwidths ranging from about 30% at 0.25 kHz to about 10% at 4 kHz. Stimuli having narrower or broader bandwidths are desirable for some special purposes. The test room should be as nonreverberant as possible and the subject should be seated on an adjustable height chair with headrest. The control microphone method of calibration is preferred but a method is also presented for carrying out the traditional precalibration procedure. The SPL of the complex stimulus should be taken as the peak deflections on a sound level meter set to "RMS-FAST." A conversion table is presented which allows thresholds obtained in the sound field to be expressed as dB HTL. With the materials and methods described here it is possible to achieve the same reliability for sound field testing as for audiometry under earphones.

Candidates for multiple frequency response characteristics

This study examined what types of subjects may benefit from the use of multiple memory hearing aids that offer variation in their frequency response characteristics. Thirty subjects with varied degrees and configurations of hearing loss compared an individually prescribed frequency response (NAL) and two variations in which the real-ear response slope was either increased (more high-frequency emphasis) or decreased by about 3 dB/octave over the range from 500 Hz to 4000 Hz. The evaluations consisted of paired comparison judgments of pleasantness and of ease of understanding speech, in quiet and in three background noises with substantially different acoustic spectra (traffic noise, speech babble, and high-frequency noise). Twelve of the 30 subjects selected different frequency responses for different background noises and/or for different response criteria. These subjects were characterized as having the more severe high-frequency hearing losses (averaged across 2000, 3000, and 4000 Hz). They also tended to be those for whom the three frequency responses provided the greatest variation in real-ear low-frequency gain. (Despite substantial electronic variations, some subjects received only small variations in real-ear gain at the low frequencies). When subjects chose a different response for different conditions, they tended to prefer responses for which the slope was negatively related to the spectrum of the stimulus. This was true for both response criteria. The conclusion is that hearing aid users with substantial high-frequency losses, and who can be fitted with sufficient variation in the low-frequency real-ear gain, have the potential to benefit from having a choice of frequency response characteristics.

The effect of a depleting anti-CD4 monoclonal antibody on T cells and fetal pig islet xenograft survival in various strains of mice

The effect of a cell-depleting anti-CD4 monoclonal antibody (mAb), GK1.5, was studied in a number of strains of inbred mice. Young adult female NOD/Lt, CBA and BALB/c mice were transplanted with organ cultured fetal pig pancreas and given 0.3 mg of the mAb (as ascites) on days -1, 0 and +1. The grafts were mostly rejected within 13 days in CBA mice but BALB/c and NOD recipients still had essentially intact grafts with the NOD mice showing evidence of early rejection. By 28 days posttransplantation the BALB/c recipients still had well-preserved grafts with minimal infiltration, but NOD and CBA mice had generally rejected their grafts totally. Peritransplant mAb treatment reduced CD4+ T cells in the spleen and they showed only incomplete recovery by 28 days. To further analyse the effect of anti-CD4 treatment, these strains as well as C57BL/6 mice were given a single dose (0.3 mg) of GK1.5 either as ascites or as affinity purified mAb. There was no obvious difference in effect between the ascites and the purified mAb within a strain but the various strains showed consistent differences in their blood, spleen and lymph node lymphocytes and in their response to the mAb. C57BL/6 mice differed from the other strains in having fewer T cells but more B cells in the blood, spleen and lymph nodes and a low CD4/CD8 ratio. Recovery of CD4+ T cells was most rapid in NOD mice and this together with the relatively high number of these cells may account for the ability of these mice to reject grafts despite immunosuppression that can allow prolonged graft survival in other strains. This study emphasizes the need to examine various strains of mice when making general statements about the efficacy of immunosuppression in transplantation and stresses the need to be aware of the frequent use of 'permissive' strains in reports where excellent graft survival is reported.

Factors affecting the use and perceived benefit of ITE and BTE hearing aids

The aim of the present study was to investigate factors that might affect hearing aid use, satisfaction and perceived benefit. A further aim was to look at which variables affect the choice of hearing aid, in particular, an in-the-ear (ITE) versus a behind-the-ear (BTE) device. Twenty-nine elderly hearing-impaired people with a mild-to-moderate hearing loss were fitted with both an ITE and a BTE hearing aid with similar electroacoustic performance. Both hearing aids were linear with output compression limiting and were fitted in a randomized order. After wearing each device for a six-week period, subj ets were asked to select the hearing aid they preferred. Variables significantly related to hearing aid choice, use and perceived benefit included ease of management, accuracy with which the NAL-R insertion gain target was achieved, earmould comfort and the type of hearing aid the client preferred initially.

Individuals' willingness to talk to their doctors about clinical trial enrollment

This study investigates whether perceived fairness of doctor-patient interactions relates to individuals' willingness to communicate with their doctors about clinical trial enrollment. It also explores how willingness to talk, the perceived fairness of interactions, and trust in doctors relate to intentions to participate in a future clinical trial. Results from a random digit dial (RDD) telephone survey of U.S. adults (N = 500) measured respondents' willingness to talk to their doctors about clinical trials and intentions to participate in future trials. Perceived fairness of interactions and trust in doctors were associated with willingness to talk about clinical trials. A negative relationship emerged between perceived fairness of interactions and intentions to participate when willingness to talk was introduced into the equation. This relationship suggested that when respondents were more willing to talk to their doctors and perceived these discussions as fair, they were also less likely to express intentions to enroll in future trials. In turn, perceiving these interactions as less fair was related to greater intention to enroll. Fairness of interactions and trust in doctors were less relevant to respondents who were less willing to talk to their doctors; however, these respondents also were more likely to express intentions to enroll in future clinical trials.

Circumferential mural bands in the small intestine causing simple obstructive colic: a case series

REASONS FOR PERFORMING STUDY

Circumferential mural band (CMB) in the small intestine is an emerging condition in Ireland. The clinical presentation is a simple obstruction of the small intestine of unknown aetiology.

HYPOTHESIS

Horses affected with CMB in the small intestine have a good prognosis following surgical decompression into the caecum.

METHODS

A retrospective study was carried out and 28 cases identified from 559 colic surgeries performed over a 5.5 year period. An exploratory celiotomy was performed in every case. A simple obstruction at the mid or distal jejunum was identified caused by a CMB, which was multiple in some cases. All of the horses except 2 had undergone a regular anthelmintic programme.

RESULTS

Manual decompression of the small intestine into the caecum resulted in resolution of the simple jejunal obstruction. A constricted segment of small intestine was resected in one case, as the degree of constriction was severe. A full thickness biopsy was taken from another case. Histopathology was performed on both samples. All horses recovered from surgery and were discharged from the hospital 7-32 days post operatively. Short-term complications were observed. Survival rate was 100% at long-term follow-up. Histopathology showed inflammatory infiltration in the submucosa, muscularis and serosa with eosinophils predominating. Parasites were not detected.

CONCLUSION AND POTENTIAL RELEVANCE

Small intestine circumferential mural bands have a good prognosis after surgical decompression of the small intestine into the caecum.

Allowing for real ear venting effects when selecting the coupler gain of hearing aids

Vents in hearing aids have two major effects on the insertion gain of a hearing aid: they let low-frequency sound in without amplification, and they reduce the low-frequency gain of sound transmitted through the hearing aid. Their net effect on low-frequency gain can thus be either negative or positive. This paper shows how to allow for both of these effects. One of the results is that for many hearing-impaired clients, there is a range of coupler gain curves which will result in the required insertion gain. The tables in this article are arranged to enable the user to specify a desired vent, and then determine the allowable range of coupler gains that will achieve a desired insertion gain to within a specified tolerance. The results of various studies comparing coupler gain and insertion gain are also compared and combined. The calculation method outlined in this paper can predict low-frequency real ear insertion gain for the individual subject with a prediction accuracy (root-mean-square-error) of 3.6 dB.